ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology

Studies have shown the presence of expanded polyQ containing proteins in brain cells related to Huntington disease (HD) and other poly-glutamine disorders. We report the use of organically modified silica (ORMOSIL) nanoparticles as an efficient non-viral gene carrier in an effort to model brain pathology associated with those disorders induced by expanded polyQ peptides. In experiment 1, plasmids expressing Hemaglutinin-tagged polypeptides with 20 glutamine repeats (Q20) or with extended 127-glutamine repeats (Q127) were complexed with ORMOSIL nanoparticles and injected twice (2 weeks apart) into the lateral ventricle of the mouse brain. Fourteen days post-injection of Q127, immunocytochemistry revealed the presence of the characteristic nuclear and cytoplasmic Q127 aggregates in numerous striatal, septal and neocortical neuronal cells as well as ubiquitin-containing aggregates indicative of the neuronal pathology. The mice receiving Q127 showed a marked increase in the reactive GFAP (+) astrocytes in striatum, septum and brain cortex, further indicating the neurodegenerative changes, accompanied by motor impairments. In experiment 2, plasmids Q20 or Q127 were complexed with ORMOSIL and were injected into the brain lateral ventricle or directly into the striatum of adult rats. In both routes of transfection, Q127 induced the appearance of reactive GFAP (+) astrocytes and activated ED1 antigen expressing microglia. An increase in the size of the lateral ventricle was also observed in rats receiving Q127. In transgenic mouse polyQ models, extensive pathologies occur outside the nervous system and the observed brain pathologies could reflect developmental effects of the toxic polyQ proteins. Our experiments show that the nervous tissue restricted expression of poly Q-extended peptides in adult brain is sufficient to evoke neuropathologies associated with HD and other polyQ disorders. Thus, nanotechnology can be employed to model pathological and behavioral aspects of genetic brain diseases in mice as well as in other species, providing a novel research tool for in vivo testing of single or multi-gene therapies.

[1]  S. W. Davies,et al.  Transgenic models of Huntington's disease. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[2]  Indrajit Roy,et al.  Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of striatal dopamine. , 2005, Brain research. Molecular brain research.

[3]  J. B. Martin,et al.  Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.

[4]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[5]  P. Kehrli,et al.  Basic fibroblast growth factor (bFGF) injection activates the glial reaction in the injured adult rat brain , 1996, Brain Research.

[6]  Tymish Y. Ohulchanskyy,et al.  Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Paras N. Prasad,et al.  Introduction to Biophotonics , 2003 .

[8]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[9]  K. Todd,et al.  Doxycycline Reduces Cleaved Caspase-3 and Microglial Activation in An Animal Model of Neonatal Hypoxia-Ischemia , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  S. W. Davies,et al.  Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.

[11]  E. Stachowiak,et al.  Gene transfer into the central nervous system using herpes simplex virus-1 vectors. , 2000, Folia morphologica.

[12]  R. Mott,et al.  Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation , 1997, Nature Genetics.

[13]  D. Tagle,et al.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[14]  N. Severs,et al.  CONNEXIN EXPRESSION IN HUNTINGTON'S DISEASED HUMAN BRAIN , 1998, Cell biology international.

[15]  S. Heck,et al.  Genetically engineered mouse models for drug discovery: new chemical genetic approaches. , 2004, Current drug discovery technologies.

[16]  R H Myers,et al.  Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus , 1991, Journal of neuropathology and experimental neurology.

[17]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[18]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Srimoyee Ghosh,et al.  A Drosophila ortholog of the human MRJ modulates polyglutamine toxicity and aggregation , 2006, Neurobiology of Disease.

[20]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[21]  S. Davis,et al.  Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. , 1997, Trends in biotechnology.

[22]  E. Stachowiak,et al.  Assessment of viral and non-viral gene transfer into adult rat brains using HSV-1, calcium phosphate and PEI-based methods. , 2005, Folia morphologica.

[23]  C. McKerlie.  Cause and effect considerations in diagnostic pathology and pathology phenotyping of genetically engineered mice (GEM). , 2006, ILAR journal.

[24]  R. Faull,et al.  The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington’s disease human brain , 2005, Neuroscience.

[25]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[26]  G. Bates,et al.  Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.

[27]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[28]  X. Fang,et al.  Control of CREB-binding Protein Signaling by Nuclear Fibroblast Growth Factor Receptor-1 , 2005, Journal of Biological Chemistry.

[29]  E. Stachowiak,et al.  Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Jergas,et al.  Basal ganglia alterations and brain atrophy in Huntington’s disease depicted by transcranial real time sonography , 1999, Journal of neurology, neurosurgery, and psychiatry.

[31]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[32]  J. S. Schneider,et al.  Astrocytic Responses to the Dopaminergic Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Cat and Mouse Brain , 1988, Journal of neuropathology and experimental neurology.